EA202090003A1 - Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка - Google Patents
Связывающие молекулы, модулирующие биологическую активность, которую проявляет клеткаInfo
- Publication number
- EA202090003A1 EA202090003A1 EA202090003A EA202090003A EA202090003A1 EA 202090003 A1 EA202090003 A1 EA 202090003A1 EA 202090003 A EA202090003 A EA 202090003A EA 202090003 A EA202090003 A EA 202090003A EA 202090003 A1 EA202090003 A1 EA 202090003A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- biological activity
- cell
- binding
- manifestates
- binding molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
В соответствии с изобретением предложены средства и способы ингибирования биологической активности клеток. В одном варианте реализации настоящего изобретения предложен способ ингибирования биологической активности в первой или второй клетке, опосредуемой связыванием двух мембранных белков, которые являются партнерами по связыванию друг для друга. Упомянутая биологическая активность ингибируется при контакте клеток с антителом или подобной антителу молекулой, способным связываться с каждым из упомянутых партнеров по связыванию, и данное связывание блокирует связывание двух партнеров по связыванию, тем самым ингибируя упомянутую биологическую активность.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17180064 | 2017-07-06 | ||
PCT/NL2018/050449 WO2019009726A1 (en) | 2017-07-06 | 2018-07-06 | BINDING MOLECULES FOR MODULATING THE BIOLOGICAL ACTIVITY EXPRESSED BY A CELL |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202090003A1 true EA202090003A1 (ru) | 2020-06-18 |
Family
ID=59295094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090003A EA202090003A1 (ru) | 2017-07-06 | 2018-07-06 | Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка |
Country Status (14)
Country | Link |
---|---|
US (2) | US11667714B2 (ru) |
EP (1) | EP3649154A1 (ru) |
JP (2) | JP7438098B2 (ru) |
KR (1) | KR20200037791A (ru) |
CN (1) | CN111094347A (ru) |
AU (1) | AU2018296067B2 (ru) |
BR (1) | BR112020000209A8 (ru) |
CA (1) | CA3068929A1 (ru) |
EA (1) | EA202090003A1 (ru) |
IL (1) | IL271817A (ru) |
PH (1) | PH12020550011A1 (ru) |
SG (1) | SG11202000014UA (ru) |
TW (1) | TW201920264A (ru) |
WO (1) | WO2019009726A1 (ru) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA202090005A1 (ru) * | 2017-07-06 | 2020-06-18 | Мерус Н.В. | Антитела, модулирующие биологическую активность, проявляемую клеткой |
BR112020019795A2 (pt) * | 2018-03-30 | 2021-01-05 | Merus N.V. | Anticorpo multivalente |
MX2021005594A (es) | 2018-11-13 | 2021-10-22 | Compass Therapeutics Llc | Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos. |
TW202102544A (zh) * | 2019-04-04 | 2021-01-16 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
MX2021004897A (es) * | 2019-04-26 | 2021-06-18 | I Mab Biopharma Us Ltd | Anticuerpos pd-l1 humano. |
CN114702587A (zh) | 2019-05-09 | 2022-07-05 | 美勒斯公司 | 用于使蛋白质多聚化的变体结构域及其分离 |
KR20230166150A (ko) | 2020-08-19 | 2023-12-06 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
CN113416249B (zh) * | 2020-10-21 | 2023-04-07 | 北京智仁美博生物科技有限公司 | 针对破伤风毒素的组合物 |
KR20230135637A (ko) * | 2021-01-28 | 2023-09-25 | 넥스트포인트 테라퓨틱스, 인코포레이티드 | 새로운 활성을 갖는 hhla2 결합제 |
EP4314061A1 (en) | 2021-03-31 | 2024-02-07 | Merus N.V. | Novel multispecific antibodies |
JP2024511589A (ja) * | 2021-03-31 | 2024-03-14 | メルス ナムローゼ フェンノートシャップ | 新規のpd-1結合ドメイン |
CN114702569B (zh) * | 2022-05-25 | 2023-01-10 | 深圳吉诺因生物科技有限公司 | Pd-l1相关疫苗及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69830901T2 (de) | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
ES2442615T5 (es) | 2002-07-18 | 2023-03-16 | Merus Nv | Producción recombinante de mezclas de anticuerpos |
EP1896582A4 (en) * | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES FOR PROGRAMMED DEATH 1 (MP-1) AND METHODS FOR TREATING CANCER USING ANTI-MP-1 ANTIBODIES ALONE OR ASSOCIATED WITH OTHER IMMUNOTHERAPIES |
EP2288715B1 (en) | 2008-04-11 | 2014-09-24 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
SG10201914027VA (en) | 2008-06-27 | 2020-03-30 | Merus Nv | Antibody producing non-human mammals |
HRP20240240T1 (hr) | 2008-12-09 | 2024-04-26 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
AU2013249985B2 (en) * | 2012-04-20 | 2017-11-23 | Merus N.V. | Methods and means for the production of Ig-like molecules |
CN110066338B (zh) * | 2012-09-27 | 2024-04-09 | 美勒斯公司 | 作为T细胞衔接器的双特异性IgG抗体 |
TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
-
2018
- 2018-07-06 TW TW107123601A patent/TW201920264A/zh unknown
- 2018-07-06 CN CN201880055254.XA patent/CN111094347A/zh active Pending
- 2018-07-06 EP EP18749179.0A patent/EP3649154A1/en active Pending
- 2018-07-06 AU AU2018296067A patent/AU2018296067B2/en active Active
- 2018-07-06 JP JP2020500083A patent/JP7438098B2/ja active Active
- 2018-07-06 KR KR1020207003655A patent/KR20200037791A/ko not_active Application Discontinuation
- 2018-07-06 US US16/628,547 patent/US11667714B2/en active Active
- 2018-07-06 EA EA202090003A patent/EA202090003A1/ru unknown
- 2018-07-06 SG SG11202000014UA patent/SG11202000014UA/en unknown
- 2018-07-06 CA CA3068929A patent/CA3068929A1/en active Pending
- 2018-07-06 WO PCT/NL2018/050449 patent/WO2019009726A1/en unknown
- 2018-07-06 BR BR112020000209A patent/BR112020000209A8/pt unknown
-
2020
- 2020-01-02 IL IL271817A patent/IL271817A/en unknown
- 2020-01-06 PH PH12020550011A patent/PH12020550011A1/en unknown
-
2022
- 2022-12-07 US US18/062,871 patent/US20240034794A1/en active Pending
-
2023
- 2023-09-08 JP JP2023146178A patent/JP2023171782A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112020000209A2 (pt) | 2020-07-21 |
KR20200037791A (ko) | 2020-04-09 |
PH12020550011A1 (en) | 2020-10-12 |
IL271817A (en) | 2020-02-27 |
US20240034794A1 (en) | 2024-02-01 |
BR112020000209A8 (pt) | 2020-08-11 |
SG11202000014UA (en) | 2020-01-30 |
AU2018296067A1 (en) | 2020-01-30 |
US11667714B2 (en) | 2023-06-06 |
JP2023171782A (ja) | 2023-12-05 |
WO2019009726A1 (en) | 2019-01-10 |
EP3649154A1 (en) | 2020-05-13 |
TW201920264A (zh) | 2019-06-01 |
US20200325227A1 (en) | 2020-10-15 |
JP7438098B2 (ja) | 2024-02-26 |
CA3068929A1 (en) | 2019-01-10 |
CN111094347A (zh) | 2020-05-01 |
AU2018296067B2 (en) | 2021-06-10 |
JP2020532280A (ja) | 2020-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202090003A1 (ru) | Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка | |
WO2019060917A3 (en) | METHODS AND COMPOSITIONS FOR SCREENING AND IDENTIFYING SPREADING MODULATORS | |
CL2019002542A1 (es) | Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap. | |
EA201990578A1 (ru) | Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой | |
EA201792442A1 (ru) | Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение | |
EA201991168A1 (ru) | Белок, связывающий простатический специфический мембранный антиген | |
CL2018003136A1 (es) | Proteínas de unión específica y usos de las mismas. | |
MX2023007520A (es) | Aglutinantes de albumina de suero mejorados. | |
CY1123932T1 (el) | Δομες πολυειδικου αντισωματος | |
MX2022012089A (es) | Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, anticuerpos de union a interleucina 8 (il-8) y usos de los mismos. | |
EA201892312A1 (ru) | Триспецифические и/или тривалентные связывающие белки | |
BR112019000512A2 (pt) | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit | |
EA201890222A1 (ru) | Полиспецифические антигенсвязывающие молекулы и их применения | |
EA201891084A1 (ru) | Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение | |
EA201591467A1 (ru) | Анти-lag-3 связывающие белки | |
ECSP19087580A (es) | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos | |
EA201890337A1 (ru) | Конструкции антитела к flt3 и cd3 | |
WO2018134235A8 (en) | Improved serum albumin binders | |
EA201992795A1 (ru) | Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе | |
EA201591814A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОЛЕКУЛЫ Fc | |
EA201500818A1 (ru) | Антитела к cd47, не вызывающие истощение тромбоцитов и красных кровяных телец, а также способы их применения | |
EA201792193A1 (ru) | Конструкции биспецифического антитела для cdh3 и cd3 | |
EA201992206A1 (ru) | Моноклональное антитело к pd-l1 | |
MX2021001418A (es) | Produccion de proteinas heteromultimericas usando celulas de mamifero. | |
EA201791918A1 (ru) | Модификация белков клеток-хозяев |